4CPS-268 Nivolumab versus pembrolizumab in secondline treatment of metastatic non-small cell lung cancer in clinical practice by Valencia Soto, CM, Villacañas Palomares, MV, Martinez Callejo, V, García-Avello Fernández-Cueto, A, Barbadillo Villanueva, S, Ochagavia Sufrategui, M, Del Río Ortega, P, Alonso Peralta, CA, Garcia De La Paz, A, Valero Domínguez, M

Get full text

5PSQ-102 Ambulatory subcutaneous biologic therapy optimisation in rheumatology: implementation over time by Lorenzo Martin, S, Villacañas Palomares, MV, Barbadillo Villanueva, S, Uriarte Estefania, F, Parra Alonso, E, Colon Lopez De Dicastillo, A

Get full text

5PSQ-029 Effectiveness and safety of evolocumab in real clinical practice by Villacañas Palomares, MV, Colón Lopez de Dicastillo, A, Gutiérrez Pérez, I, Uriarte Estefania, F, Santos del Prado, R, Lorenzo Martin, S, Parra Alonso, E

Get full text

4CPS-025 Suitability of sacubitril valsartan prescriptions in a health management area by Soto, CM Valencia, Hurtado, J Pastor, Guzmán, MD Toscano, Herrera, S Guijarro, Palomares, MV Villacañas, Miguel, S Cortés de, González, JM Ruiz, Márquez, E Román

Get full text

DI-034 Drug usage evaluation of abiraterone in metastasic castration resistant prostate cancer: 4 Years of experience by Palomares, MV Villacañas, Fernández, EM Sáez, García, G Martín, Domínguez, E Fernández, Hernández, MV Calvo

Get full text

4CPS-103 Second-generation tyrosin kinase inhibitors in front-line therapy. comparing responses by Soto, CM Valencia, López-Sepúlveda, R, Artime-Rodríguez-Hermida, F, Herrera, S Guijarro, Villacañas-Palomares, MV, Gómez, P Nieto, Miguel, S Cortes-de

Get full text